A team of researchers have found that a new vaccine strategy tested in mice provides stronger and more lasting protection from tuberculosis (TB) infection than the BCG vaccine that is currently used in humans. Their findings were published online on January 23rd in the journal Nature Medicine.
The study was co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Bill & Melinda Gates Foundation. It was coordinated by the NIAID-funded TB Vaccine Testing and Research Materials program at Colorado State University, an initiative to speed the development of new TB vaccines and treatments.
Caused by the bacterium Mycobacterium tuberculosis (Mtb), TB remains one of the major causes of disability and death worldwide, with an estimated 1.7 million deaths in 2009 and increasing rates of drug-resistant disease. The BCG vaccine, the only one approved for human use, provides some protection against initial TB illness but does not prevent latent infection, in which Mtb persists in human cells for years and may later develop into active disease.